Regulating the Beta Cell Mass as a Strategy for Type-2 Diabetes Treatment

E-ISSN： 1873-5592|16|5|516-524

ISSN： 1389-4501

Source： Current Drug Targets, Vol.16, Iss.5, 2015-01, pp. : 516-524

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beta-cell Management in Type 2 Diabetes: Beneficial Role of Nutraceuticals

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 16, Iss. 2, 2016-09 ,pp. : 89-98

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus: Focus on Lipid-Regulating Therapy

By Woodman Richard J. Chew Gerard T. Watts Gerald F.

Drugs, Vol. 65, Iss. 1, 2005-01 ,pp. : 31-74

Adis International

Access to resources Recommend Favorite

Can't beta dose of vildagliptin for β-cell function in type 2 diabetes

Inpharma, Vol. 1, Iss. 1597, 2007-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Dapagliflozin for the treatment of type 2 diabetes

By Abdul-Ghani Muhammad A DeFronzo Ralph A

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1695-1703

Informa Healthcare

Access to resources Recommend Favorite

Thiazolidinediones in the treatment of Type 2 diabetes

By Greenberg Andrew S Pittas Anastassios G

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 5, 2002-05 ,pp. : 529-540

Informa Healthcare

Access to resources Recommend Favorite